Literature DB >> 11283081

High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

R W Shafer1, K Hertogs, A R Zolopa, A Warford, S Bloor, B J Betts, T C Merigan, R Harrigan, B A Larder.   

Abstract

We assessed the reproducibility of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and protease sequencing using cryopreserved plasma aliquots obtained from 46 heavily treated HIV-1-infected individuals in two laboratories using dideoxynucleotide sequencing. The rates of complete sequence concordance between the two laboratories were 99.1% for the protease sequence and 99.0% for the RT sequence. Approximately 90% of the discordances were partial, defined as one laboratory detecting a mixture and the second laboratory detecting only one of the mixture's components. Only 0.1% of the nucleotides were completely discordant between the two laboratories, and these were significantly more likely to occur in plasma samples with lower plasma HIV-1 RNA levels. Nucleotide mixtures were detected at approximately 1% of the nucleotide positions, and in every case in which one laboratory detected a mixture, the second laboratory either detected the same mixture or detected one of the mixture's components. The high rate of concordance in detecting mixtures and the fact that most discordances between the two laboratories were partial suggest that most discordances were caused by variation in sampling of the HIV-1 quasispecies by PCR rather than by technical errors in the sequencing process itself.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283081      PMCID: PMC87964          DOI: 10.1128/JCM.39.4.1522-1529.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

Authors:  J Durant; P Clevenbergh; P Halfon; P Delgiudice; S Porsin; P Simonet; N Montagne; C A Boucher; J M Schapiro; P Dellamonica
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

2.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype.

Authors:  C Verhofstede; F V Wanzeele; B Van Der Gucht; N De Cabooter; J Plum
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

3.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.

Authors:  H L Devereux; M Youle; M A Johnson; C Loveday
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

4.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  R W Shafer; D R Jung; B J Betts; Y Xi; M J Gonzales
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

5.  Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.

Authors:  H F Günthard; J K Wong; C C Ignacio; D V Havlir; D D Richman
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-01       Impact factor: 2.205

Review 6.  Retrovirus mutation rates and their role in genetic variation.

Authors:  L M Mansky
Journal:  J Gen Virol       Date:  1998-06       Impact factor: 3.891

7.  Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.

Authors:  L M Demeter; R D'Aquila; O Weislow; E Lorenzo; A Erice; J Fitzgibbon; R Shafer; D Richman; T M Howard; Y Zhao; E Fisher; D Huang; D Mayers; S Sylvester; M Arens; K Sannerud; S Rasheed; V Johnson; D Kuritzkes; P Reichelderfer; A Japour
Journal:  J Virol Methods       Date:  1998-11       Impact factor: 2.014

8.  HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

Authors:  A R Zolopa; R W Shafer; A Warford; J G Montoya; P Hsu; D Katzenstein; T C Merigan; B Efron
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

9.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing.

Authors:  B A Larder; A Kohli; P Kellam; S D Kemp; M Kronick; R D Henfrey
Journal:  Nature       Date:  1993-10-14       Impact factor: 49.962

10.  Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  R Schuurman; L Demeter; P Reichelderfer; J Tijnagel; T de Groot; C Boucher
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

View more
  39 in total

1.  Reverse transcriptase and protease sequence evolution in two HIV-1-infected couples.

Authors:  Sarah Palmer; Dominique Vuitton; Matthew J Gonzales; Agnés Bassignot; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2002-11-01       Impact factor: 3.731

2.  HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.

Authors:  Jaideep Ravela; Bradley J Betts; Francoise Brun-Vézinet; Anne-Mieke Vandamme; Diane Descamps; Kristel van Laethem; Kate Smith; Jonathan M Schapiro; Dean L Winslow; Caroline Reid; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2003-05-01       Impact factor: 3.731

3.  Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Authors:  Conan K Woods; Chanson J Brumme; Tommy F Liu; Celia K S Chui; Anna L Chu; Brian Wynhoven; Tom A Hall; Christina Trevino; Robert W Shafer; P Richard Harrigan
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

4.  Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.

Authors:  D C Sayer; S Land; L Gizzarelli; M French; G Hales; S Emery; F T Christiansen; E M Dax
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

5.  Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.

Authors:  R A Galli; B Sattha; B Wynhoven; M V O'Shaughnessy; P R Harrigan
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy.

Authors:  Rami Kantor; Robert W Shafer; Stephen Follansbee; Jonathan Taylor; David Shilane; Leo Hurley; Dong-Phuong Nguyen; David Katzenstein; W Jeffrey Fessel
Journal:  AIDS       Date:  2004-07-23       Impact factor: 4.177

7.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

8.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

Authors:  Galina N Nikolenko; Sarah Palmer; Frank Maldarelli; John W Mellors; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

9.  HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.

Authors:  Soo-Yon Rhee; W Jeffrey Fessel; Andrew R Zolopa; Leo Hurley; Tommy Liu; Jonathan Taylor; Dong Phuong Nguyen; Sally Slome; Daniel Klein; Michael Horberg; Jason Flamm; Stephen Follansbee; Jonathan M Schapiro; Robert W Shafer
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

10.  Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Authors:  Jennifer E Foulkes-Murzycki; Christina Rosi; Nese Kurt Yilmaz; Robert W Shafer; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.